⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607 | 0.83 | TSHR (0.39) | — | |
| SCHEMBL1251073 | 0.82 | MEN1 (0.61) | — | |
| Fluoride SCHEMBL1811141 | 0.80 | TSHR (0.37) | — | |
| Trimethylammonium SCHEMBL5918857 | 0.80 | TSHR (0.37) | — | |
| Fluoride SCHEMBL28910326 | 0.80 | TSHR (0.37) | — | |
| Ammonia Solution, Strong SCHEMBL1170676 | 0.80 | TSHR (0.37) | — | |
| Bromide SCHEMBL8460965 | 0.80 | TSHR (0.37) | — | |
| SCHEMBL17703415 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL8075611 | 0.80 | TSHR (0.37) | — | |
| Ethylene Glycol SCHEMBL28558188 | 0.80 | TSHR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7634 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970711-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-30 | — | — | US | claimed |
| CN-117083385-A | Targeting oncogenic mutations with double-cleaving endonucleases | 特定生物制品公司 | 2023-11-17 | — | — | CN | claimed |
| CN-117003652-A | N, N-dimethylamino glycol ether, preparation thereof and application thereof as regulator of polymeric structure | 中国石油化工股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| US-11795472-B2 | RNA-guided nucleic acid modifying enzymes and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-24 | — | — | US | claimed |
| WO-2023201203-A2 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-19 | — | — | WO | claimed |
| EP-4240839-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | Specific Biologics Inc. (CA) | 2023-09-13 | — | — | EP | claimed |
| CN-116669775-A | Gene editing with modified endonucleases | 特定生物制品公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2023107531-A2 | ANTISENSE OLIGONUCLEOTIDE DRUG TARGETS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-15 | — | — | WO | claimed |
| US-11674159-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-13 | — | — | US | claimed |
| US-20230174979-A1 | METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA | CHILDREN’S MEDICAL CENTER CORPORATION (US) | 2023-06-08 | — | — | US | claimed |
| EP-1119579-A4 | ANTISENSE MODULATION OF BCL-X EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2003-01-29 | — | — | EP | claimed |
| EP-1263765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-11 | — | — | EP | claimed |
| JP-2002526093-A | — | — | 2002-08-20 | — | — | JP | claimed |
| WO-2001072765-A1 | ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING | ISIS PHARMACEUTICALS, INC. (US) | 2001-10-04 | — | — | WO | claimed |
| EP-1119579-A1 | ANTISENSE MODULATION OF BCL-X EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-08-01 | — | — | EP | claimed |
| US-20010007025-A1 | Antisense modulation of bcl-x expression | ISIS PHARMACEUTICALS, INC. | 2001-07-05 | — | — | US | claimed |
| US-6214986-B1 | OLIGONUCLEOTIDE OF DEFINED NUCLEOTIDE SEQUENCE TARGETED TO HUMAN PROTEIN WHICH CONTROLS APOPTOSIS; ALTERS RATIOS OF ISOFORMS IN TISSUE; GENE EXPRESSION INHIBITION; SENSITIZING CELLS TO APOPTOTIC STIMULI | ISIS PHARMACEUTICALS, INC. | 2001-04-10 | — | — | US | claimed |
| US-6210892-B1 | HYBRIDIZING AN ANTISENSE COMPOUND HAVING A 2' SUGAR, MORPHOLINO, OR PEPTIDE NUCLEIC ACID MODIFICATION TO TARGET MESSENGER RNA TO CHANGE ITS PROCESSING INCLUDING SPLICING, POLYADENYLATION OR STABILITY | ISIS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | claimed |
| WO-2000020432-A1 | ANTISENSE MODULATION OF BCL-X EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | claimed |
| WO-2000004189-A1 | MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |